By Daniella Parra
Inventiva said Dr. Jason Campagna has been named President of R&D and Chief Medical Officer as Inventiva advances lanifibranor, its lead candidate for MASH, with topline Phase 3 results from the NATiV3 trial expected in the second half of 2026.
Dr. Martine Zimmermann joins as Executive Vice President of Regulatory Affairs and Quality Assurance. Both bring extensive experience in liver disease drug development and regulatory strategy, the company said.
” Having led the design and execution of one of the field’s most advanced clinical programs at Intercept—including the first-ever NDA submission in this indication—I’ve seen firsthand both the scientific complexity and the urgency of bringing effective therapies to patients with MASH,” Jason Campagna, MD, PhD, President of Inventiva said. “I believe the promising results of the Phase 2b NATIVE trial reflect the thoughtful design of lanifibranor development program—and that’s deeply exciting to me.”
READ MORE HEALTHCAREEDGE
Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug
Register for our weekly newsletter HERE
